Table 1.
Specificity of the test: Absence of interference by fibrin degradation products.
Figure 1.
Evolution of SF and D-dimer levels in patients under anticoagulant therapy.
SF and D-dimer (D-Di) concentrations were determined daily in patients before and after starting anticoagulant therapy.
Figure 2.
ROC Curves established for Pulmonary Embolism and for Deep Vein Thrombosis Open squares : Sensitivity Closed square : Specificity.
Table 2.
Roc appendices for pulmonary embolism and for deep vein thrombosis.
Table 3.
Plasma Soluble Fibrin (SF) and D-dimer levels in Patients with suspected Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT).
Figure 3.
Distribution of the levels of SF and D-dimer in patients with suspected pulmonary embolism (PE) or deep vein thrombosis.
Evaluation of median and 25th and 75th percentiles. (A) Soluble fibrin concentration. (B) D-dimer concentration. •/Closed circles: patients with PE or DVT; ○/open circles, patients without PE or DVT. The bars depict the median with interquartile ranges. The double broken bars represent the upper normal value.
Table 4.
Evaluation of the area under the ROC (Receiving Operating Characteristic) curve for SF and D-dimer derived from patients with suspected Pulmonary Embolism or Deep Vein Thrombosis.
Table 5.
Sensitivity, Specificity, Positive- (PPV) and Negative-Predictive Values (NPV) (95% Confidence Intervals) for Soluble Fibrin (SF) and D-dimer concentrations in Pulmonary Embolism and Deep Vein Thrombosis.